These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18989351)

  • 1. Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma.
    Lortal B; Gross F; Peron JM; Pénary M; Berg D; Hennebelle I; Favre G; Couderc B
    Cancer Gene Ther; 2009 Apr; 16(4):329-37. PubMed ID: 18989351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer.
    Elder EM; Lotze MT; Whiteside TL
    Hum Gene Ther; 1996 Mar; 7(4):479-87. PubMed ID: 8800742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large preclinical animal model to assess ex vivo skin gene therapy applications.
    Pfützner W; Joari MR; Foster RA; Vogel JC
    Arch Dermatol Res; 2006 Jun; 298(1):16-22. PubMed ID: 16565820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene therapy of liver tumors].
    Panis Y; Charre L; Alves A; Soubrane O
    J Chir (Paris); 2000 Dec; 137(6):317-24. PubMed ID: 11119025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene therapy in liver diseases].
    Pár A; Lakatos PL; Abonyi M; Szalay F; Nagy Z; Mózsik G
    Orv Hetil; 2002 Jan; 143(3):125-9. PubMed ID: 11883109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
    Ghani K; Cottin S; Kamen A; Caruso M
    Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant adeno-associated virus derived vectors (rAAV2) efficiently transduce ovarian and hepatocellular carcinoma cells--implications for cancer gene therapy.
    Małecki M; Swoboda P; Pachecka J
    Acta Pol Pharm; 2009; 66(1):93-9. PubMed ID: 19226976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cells as vehicles for therapeutic genes to treat liver diseases.
    Prieto J; Fernandez-Ruiz V; Kawa MP; Sarobe P; Qian C
    Gene Ther; 2008 May; 15(10):765-71. PubMed ID: 18385768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retroviral vectors for clinical immunogene therapy are stable for up to 9 years.
    Lamers CH; van Elzakker P; Luider BA; van Steenbergen SC; Sleijfer S; Debets R; Gratama JW
    Cancer Gene Ther; 2008 Apr; 15(4):268-74. PubMed ID: 18202714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimising stable retroviral transduction of primary human synovial fibroblasts.
    Paya M; Segovia JC; Santiago B; Galindo M; del Rio P; Pablos JL; Ramírez JC
    J Virol Methods; 2006 Oct; 137(1):95-102. PubMed ID: 16839616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The skin as a biofactory for systemic secretion of erythropoietin: potential of genetically modified keratinocytes and fibroblasts.
    Scheidemann F; Löser M; Niedermeier A; Kromminga A; Therrien JP; Vogel J; Pfützner W
    Exp Dermatol; 2008 Jun; 17(6):481-8. PubMed ID: 18331333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy in skin: choosing the optimal viral vector.
    Teo EH; Cross KJ; Bomsztyk ED; Lyden DC; Spector JA
    Ann Plast Surg; 2009 May; 62(5):576-80. PubMed ID: 19387165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for liver tumors.
    Panis Y; Rad AR; Boyer O; Houssin D; Salzmann JL; Klatzmann D
    Surg Oncol Clin N Am; 1996 Apr; 5(2):461-73. PubMed ID: 9019365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.
    Przybylowski M; Hakakha A; Stefanski J; Hodges J; Sadelain M; Rivière I
    Gene Ther; 2006 Jan; 13(1):95-100. PubMed ID: 16177816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic poly(L-lysine)-b-Poly(L-lactide)-b-dendritic poly(L-lysine) amphiphilic gene delivery vectors: roles of PLL dendritic generation and enhanced transgene efficacies via termini modification.
    Li Y; Zhu Y; Xia K; Sheng R; Jia L; Hou X; Xu Y; Cao A
    Biomacromolecules; 2009 Aug; 10(8):2284-93. PubMed ID: 19586045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene therapy for hepatocellular carcinoma. From the idea to clinical trials].
    Gerolami R; Uch R; Cardoso J; Bagnis C; Mannoni P; Bréchot C
    Gastroenterol Clin Biol; 2001 Mar; 25(3):273-86. PubMed ID: 11395675
    [No Abstract]   [Full Text] [Related]  

  • 17. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
    Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
    J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy.
    Wikström K; Blomberg P; Islam KB
    Biotechnol Prog; 2004; 20(4):1198-203. PubMed ID: 15296448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hemophilia: clinical trials and technical tribulations.
    Viiala NO; Larsen SR; Rasko JE
    Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Release testing of retroviral vectors and gene-modified cells.
    Nordling D; Kaiser A; Reeves L
    Methods Mol Biol; 2009; 506():265-79. PubMed ID: 19110632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.